Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Hemo Organic Ltd

HEMORGANIC
BSE
11.00
1.66%
Last Updated:
30 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Hemo Organic Ltd

HEMORGANIC
BSE
11.00
1.66%
30 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
4Cr
Close
Close Price
11.00
Industry
Industry
Trading
PE
Price To Earnings
37.93
PS
Price To Sales
1.58
Revenue
Revenue
2Cr
Rev Gr TTM
Revenue Growth TTM
11,950.00%
PAT Gr TTM
PAT Growth TTM
-123.08%
Peer Comparison
How does HEMORGANIC stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
HEMORGANIC
VS

Quarterly Results

Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
000000002000
Growth YoY
Revenue Growth YoY%
11,950.0
Expenses
ExpensesCr
000000002000
Operating Profit
Operating ProfitCr
000000000000
OPM
OPM%
-1,050.05.8
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
000000000000
Tax
TaxCr
000000000000
PAT
PATCr
000000000000
Growth YoY
PAT Growth YoY%
-400.0-360.0100.0-900.0260.962.5-100.0
NPM
NPM%
-1,150.015.3
EPS
EPS
-0.1-0.10.00.0-0.70.0-0.2-0.21.1-0.3-0.1-0.5

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
001000000022
Growth
Revenue Growth%
-77.7-29.9439.3-85.5-37.1407.5-97.1-15.4-29.7366.710,678.1-0.2
Expenses
ExpensesCr
001000000022
Operating Profit
Operating ProfitCr
000000000000
OPM
OPM%
-38.4-50.2-13.1-170.4-219.7-7.9-593.2-911.6-1,137.5-1,099.1-1.8-2.9
Other Income
Other IncomeCr
0-10000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
0-10000000000
Tax
TaxCr
000000000000
PAT
PATCr
0-10000000000
Growth
PAT Growth%
-391.5-679.490.4-88.218.981.8-119.3-30.312.5-383.7162.1-45.1
NPM
NPM%
-66.7-741.5-13.1-170.3-219.7-7.9-593.2-913.1-1,137.5-1,179.06.83.7
EPS
EPS
-0.3-2.4-0.2-0.4-0.3-0.1-0.1-0.2-0.2-0.80.50.3

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
333333333333
Reserves
ReservesCr
-2-3-3-3-3-3-3-3-4-4-4-4
Current Liabilities
Current LiabilitiesCr
001110000044
Non Current Liabilities
Non Current LiabilitiesCr
000000000112
Total Liabilities
Total LiabilitiesCr
111110000155
Current Assets
Current AssetsCr
001110000155
Non Current Assets
Non Current AssetsCr
100000000000
Total Assets
Total AssetsCr
111110000155

Cash Flow

Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
0-10000000-10
Investing Cash Flow
Investing Cash FlowCr
01000000000
Financing Cash Flow
Financing Cash FlowCr
00000000010
Net Cash Flow
Net Cash FlowCr
00000000000
Free Cash Flow
Free Cash FlowCr
000000000-10
CFO To PAT
CFO To PAT%
-61.494.8193.581.635.4-27.328.87.1-196.2450.8-220.7
CFO To EBITDA
CFO To EBITDA%
-106.71,401.3193.581.635.4-27.328.87.1-196.2483.6816.5

Ratios

Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
376504518243
Price To Earnings
Price To Earnings
0.00.00.00.00.00.00.00.00.00.019.1
Price To Sales
Price To Sales
19.559.310.255.90.014.4507.01,780.0177.01.3
Price To Book
Price To Book
2.515.315.219.60.035.176.85,130.0-47.3-11.2-20.4
EV To EBITDA
EV To EBITDA
-50.7-115.6-76.5-34.4-0.5-183.5-106.3-286.3-43.6-18.9-103.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
19.237.811.59.3-28.831.144.3-36.566.731.78.9
OPM
OPM%
-38.4-50.2-13.1-170.4-219.7-7.9-593.2-911.6-1,137.5-1,099.1-1.8
NPM
NPM%
-66.7-741.5-13.1-170.3-219.7-7.9-593.2-913.1-1,137.5-1,179.06.8
ROCE
ROCE%
-8.2-197.3-19.5-43.7-54.9-18.9-47.5-161.8341.3-26.71.9
ROE
ROE%
-8.5-197.3-19.5-57.9-88.6-19.2-72.8-1,816.2106.683.7-108.2
ROA
ROA%
-7.7-153.2-6.9-14.8-12.6-8.8-20.5-26.1-15.9-24.83.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Hemo Organic Limited is an Indian public entity currently undergoing a fundamental strategic pivot. Historically a manufacturer of **Ayurvedic** and **Unani** preparations, the company is transitioning into a diversified **Trading and Distribution** powerhouse. This transformation is characterized by aggressive capital raising, a complete overhaul of the management team, and an expansion of its constitutional mandate to include high-growth sectors such as **Agri-commodities**, **Textiles**, and **Metals**. --- ### **Strategic Pivot: From Niche Manufacturing to Multi-Sector Trading** The company has formally amended its **Main Object Clause** in the Memorandum of Association to facilitate a move away from its legacy chemical and organic roots. The current operational scope now encompasses: * **Agri-Commodities:** Focused on the trading and distribution of **Rice** and other food grains. * **Textiles:** Trading in a wide array of fabrics including **Silk, Synthetic, Woolen, and Cotton**, as well as yarn and readymade garments. * **Metals (Authorized):** Strategic intent to trade, import, and export **Copper** and copper alloys, including scrap, foils, wires, and sheets. * **Pharmaceuticals & Life Sciences:** Retaining and expanding its footprint in the manufacturing and retail of medicines, **biologicals**, **nutraceuticals**, and dietary supplements. --- ### **Capital Restructuring and Funding Roadmap** To support its new business lines and address liquidity needs, Hemo Organic is executing a multi-pronged financial strategy: * **Preferential Issue (February 2026):** Allotment of **3,400,000 Convertible Warrants** at **Rs. 12.50** per warrant (inclusive of a **Rs. 2.50 premium**). These are convertible into equity within **18 months**, which will effectively double the paid-up equity capital from **Rs. 3.46 Crores** to **Rs. 6.86 Crores**. * **Rights Issue (March 2025):** The company has filed a Draft Letter of Offer with the **BSE** for a Rights Issue seeking to aggregate up to **Rs. 20.00 Crores**. * **Expanded Borrowing Mandate:** Shareholders have authorized an increase in borrowing limits up to **Rs. 100 Crores** to facilitate both organic growth and potential inorganic acquisitions. * **Debt-to-Equity Flexibility:** Provision for up to **Rs. 5.00 Crores** in unsecured loans from directors/promoters, with the option to convert this debt into equity. * **Authorized Capital Growth:** Reflecting its expansionary scale, the company increased its **Authorised Share Capital** from **Rs. 3.50 Crores** (August 2024) to **Rs. 13.45 Crores** (January 2026). --- ### **Operational Infrastructure and Relocation** The company has shifted its administrative and operational hub to Ahmedabad to better align with its trading objectives. | Feature | Details | | :--- | :--- | | **Registered Office (New)** | **Uttamnagar, Ahmedabad** (Effective Feb 2026); previously Sumel Business Park 7, Ahmedabad. | | **Primary Segment** | **Single Segment**: Trading and Distribution. | | **Accounting Standard** | **Ind AS** (Indian Accounting Standards). | | **Use of Proceeds** | **75%** for Working Capital and Infrastructure; **25%** for General Corporate Purposes. | --- ### **Leadership and Governance Transition** A significant management refresh occurred in **May 2024**, aimed at stabilizing the company’s administrative and compliance functions: * **Mr. Vishwambar Kameshwar Singh (Managing Director):** Appointed May 29, 2024. He oversees administration, HR, and business expansion. Notably, he serves **without financial compensation**, signaling a commitment to the company's turnaround. * **Mr. Murlidhar Joshi (CFO):** Appointed May 29, 2024, to lead financial recovery. * **Ms. Garima Dineshkumar Jain (Company Secretary):** Serves as the Compliance Officer. * **Board Expertise:** The board includes independent directors with specialized backgrounds in **Capital Markets** (Mr. Deepak Ashokkumar Rochani) and **Legal/Secretarial Compliances** (Ms. Hiral Vinodbhai Patel). --- ### **Critical Risk Factors and Audit Qualifications** Investors should note that Hemo Organic faces substantial financial and regulatory headwinds that challenge its "going concern" status. #### **1. Financial Instability** * **Negative Net Worth:** As of **March 31, 2025**, accumulated losses have fully eroded the company’s **paid-up capital and reserves**. * **Liquidity Deficit:** Current liabilities consistently exceed current assets, leading to persistent net losses. #### **2. Persistent Audit Qualifications** Statutory auditors have issued **Qualified Opinions** for several years (FY 2023-24 through Feb 2026) citing: * **Unconfirmed Balances:** A lack of third-party confirmations for **Trade Receivables** and **Trade Payables**. * **Banking Discrepancies:** Inability to verify transactions for **4 out of 5 bank accounts** (claimed as dormant by management). * **Accounting Non-compliance:** Failure to charge **depreciation** on fixed assets and non-adherence to **Ind AS** regarding Deferred Tax Assets/Liabilities. * **Audit Trail:** The accounting software lacks the mandatory **edit log (audit trail)** facility required by law. #### **3. Regulatory and Compliance History** | Compliance Area | Status / Risk Detail | | :--- | :--- | | **BSE Listing Status** | Flagged as **'SDD Non-compliant'** (System Driven Disclosures) as of Sept 2025. | | **KMP Vacancies** | History of significant delays in appointing a **Company Secretary** and **CFO** (e.g., CS post vacant for 20 months). | | **Fines and Penalties** | Previous penalties imposed by **BSE** for **Regulation 6(1)** violations and late payment of **Annual Listing/Custody Fees**. | | **Internal Audit** | Non-compliance with **Section 138** of the Companies Act for **FY 2022-23**. | --- ### **Market and Macroeconomic Exposure** The company’s performance is highly sensitive to external variables: * **Climatic Dependency:** The **Rice** trading business is vulnerable to **monsoon patterns** and irregular rainfall, which directly impact supply and pricing. * **Sector Volatility:** Exposure to the **Indian Chemical Industry** (projected at **US$ 304 billion by 2025**) and the cyclical nature of the textile and agrochemical markets. * **Policy and Geopolitics:** Reliance on government policy for food grain exports and vulnerability to **currency fluctuations** and trade restrictions. * **Competitive Landscape:** The trading sector has low entry barriers, leading to high competition and potential volatility in the investor base.